Ubs
Latest news, explainers and analysis on Ubs. Tracking 5 stories on Arth Vani.
Connected in the graph
Latest on Ubs
Moderna Stock: UBS Issues Rare 'Sell' Rating, Foresees 44% Price Drop
Investment bank UBS has issued a rare 'sell' rating on biotech firm Moderna, projecting a significant 44% decline in its stock price. This downgrade comes despite recent investor optimism surrounding Moderna's advancements in cancer vaccines, with UBS citing concerns over the company's valuation.
UBS Buys Back Credit Suisse Bonds to Calm Markets Post-Acquisition
UBS has announced plans to buy back over ₹24,960 crore ($3 billion) of Credit Suisse debt to simplify its capital structure and reduce funding costs after acquiring its rival. This move aims to boost investor confidence following the tumultuous takeover and the controversial write-down of Credit Suisse's riskiest bonds earlier this year.
UBS Updates AMD Stock Target Following Key AI Day Signals
Investment bank UBS has revised its stock price target for semiconductor giant Advanced Micro Devices (AMD), in response to signals and developments from the company's recent 'AI Day' event. This move indicates a keen analyst focus on AMD's strategies and product pipeline within the booming artificial intelligence sector, reflecting the dynamic nature of global tech markets.
BlackRock Earnings Expected: What UBS Analysts Predict for Investors
Global investment giant BlackRock is set to release its earnings report soon. Analysts at UBS are optimistic, suggesting positive trends that could impact the broader investment landscape. Investors are keenly watching for insights into asset management performance and market outlook.
Motilal Oswal Shares Surge 5% as UBS Issues ‘Buy’ Rating on Growth Outlook
Shares of Motilal Oswal Financial Services climbed on Friday following a positive outlook from global brokerage UBS. The firm highlighted India’s increasing shift toward financial assets and the company's rising recurring revenue as key growth drivers.
Mutual fund data is sourced from AMFI and shown for information only — funds are subject to market risks. Read all scheme-related documents carefully. Some listings may be sponsored. Not investment advice.